Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells

Molecular Immunology

Volumn 48, Issue 1-3, 2010, Pages 98-108

  Hernández, Tays ^a   de Acosta, Cristina Mateo ^a   López Requena, Alejandro ^a   Moreno, Ernesto ^a   Alonso, Ruby ^a   Fernández Marrero, Yuniel ^a   Pérez, Rolando ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Alpha type anti idiotypic antibodies; Antibody binding site; B CLL; Fc RIIb

Indexed keywords

ALPHA TYPE ANTI IDIOTYPIC ANTIBODY; B7Y33 ANTIBODY; CHIMERIC ANTIBODY; FC RECEPTOR; ISOPROTEIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIBODY COMBINING SITE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HEAVY CHAIN VARIABLE REGION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MOLECULAR INTERACTION; MOUSE; MUTANT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLEEN CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; CELL LINE; CELL SEPARATION; COMPLEMENTARITY DETERMINING REGIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECEPTORS, IGG;

MURINAE;

EID: 78649496540     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.09.006     Document Type: Article

References (55)

1. Alfonso M., Vázquez A.M., Carr A., Haerslev T., Fernández L.E., Lanio M.E., Alvarez C., Zeuthen J., Pérez R. T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Hybridoma 1995, 14:209-216.
2. Amigorena S., Bonnerot C., Choquet D., Fridman W.H., Teillaud J.L. Fc gamma RII expression in resting and activated B lymphocytes. Eur. J. Immunol. 1989, 19:1379-1385.
3. Bayer E.A., Wilchek M. The use of avidin-biotin complex as a tool in molecular biology. Methods Biochem. Anal. 1980, 26:1-45.
4. Betáková T., Vareckova E., Kostolansky F., Mucha V., Daniels R.S. Monoclonal anti-idiotypic antibodies mimicking the immunodominant epitope of influenza virus haemagglutinin elicit biologically significant immune responses. J. Gen. Vir. 1998, 79:461-470.
5. Bond C.J., Wiesmann C., Marsters J.C., Sidhu S.S. A structure-based database of antibody variable domain diversity. J. Mol. Biol. 2005, 348:699-709.
6. Brooks D.G., Qiu W.Q., Luster A.D., Ravetch J.V. Structure and expression of human IgG FcRII (CD32). Functional heterogeneity is encoded in alternatively spliced products of multiple genes. J. Exp. Med. 1989, 170:1369-1385.
7. Callanan M.B., Le Baccon P., Mossuz P., Duley S., Bastard C., Hamoudi R., Dyer M.J., Klobeck G., Rimokh R., Sotto J.J., Leroux D. The IgG Fc receptor FcgRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:309-314.
8. Camilleri-Broët S., Cassard L., Broët P., Delmer A., Le Touneau A., Diebold J., Fridman W.H., Molina T.J., Sautès-Fridman C. FcgammaRIIB is differentially expressed during B cell maturation and in B cell lymphomas. Br. J. Haematol. 2004, 124:55-62.
9. Carr A., Mullet A., Mazorra Z., Vázquez A.M., Alfonso M., Mesa C., Rengifo E., Pérez R., Fernández L.E. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000, 19:241-247.
10. Coloma M.J., Hastings A., Wims L.A., Morrison S.L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods 1992, 152:89-104.
11. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004, 5:317-328.
12. Gillet L., May J.S., Colaco S., Stevenson P.G. The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization. PLoS One 2007, 2:e705.
13. Helling F., Shang A., Calves M., Zhang S., Ren S., Yu R.K., Oettgen H.F., Livingston P.O. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 1994, 54:197-203.
14. Helling F., Zhang S., Shang A., Adluri S., Calves M., Koganty R., Longenecker B.M., Yao T.-J., Oettgen H.F., Livingston P.O. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995, 55:2783-2788.
15. Hernández A.M., Rodríguez M., López-Requena A., Beausoleil I., Pérez R., Vázquez A.M. Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 2005, 210:11-21.
16. Hernández T., López-Requena A., Mateo de Acosta C., Mustelier G., Roque-Navarro L., Pérez R. B7 and 34B7 monoclonal antibodies: a theoretical approach to the molecular basis of immunoglobulin cross-reactive antibodies. Hybridoma (Larchmt). 2007, 26:66-72.
17. Hinojosa L.E., Hernández T., Mateo de Acosta C., Montero E., Pérez R., López-Requena A. Construction of a recombinant non-mitogenic anti-human CD3 antibody. Hybridoma 2010, 29:115-124.
18. Huizinga T.W., Kerst M., Nuyens J.H., Vlug A., von dem Borne A.E., Roos D., Tetteroo P.A. Binding characteristics of dimeric IgG subclass complexes to human-neutrophils. J. Immunol. 1989, 142:2359-2364.
19. Jerne N.K. Towards a network theory of the immune system. Ann. Immunol. 1974, 125:373-389.
20. Kabat, E.A., Wu, T.T., Perry, H.M., Gotessmann, K.S., Foeller, C., 1991. Sequences of proteins of immunological interest. Dept of Health and Human Service. US Government Printing Office.
21. Kannagi R., Yin J., Miyazaki K., Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim. Biophys. Acta 2008, 1780:525-531.
22. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin (IVIg). N. Engl. J. Med. 2001, 345:747-755.
23. Kohler H. Superantibodies: synergy of innate and acquired immunity. Appl. Biochem. Biotechnol. 2000, 83:1-9.
24. Kohler H., Paul S. Superantibody activities: new players in innate and adaptive immune responses. Immunol. Today 1998, 19:221-227.
25. Krause I., Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods Mol. Med. 2005, 109:403-408.
26. Livingston P.O., Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. Previous experience and future. Cancer Immunol. Immunother. 1997, 45:10-19.
27. López-Requena A., Mateo de Acosta C., Moreno E., González M., Puchades Y., Talavera A., Vispo N.S., Vázquez A.M., Pérez R. Gangliosides Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. Mol. Immunol. 2007, 44:423-433.
28. López-Requena A., Mateo de Acosta C., Pérez A., Valle A., Lombardero J., Sosa K., Pérez R., Vázquez A.M. Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics 2003, 22:235-243.
29. López-Requena A., Mateo De Acosta C., Vázquez A.M., Pérez R. Immunogenicity of autologous immunoglobulins: principles and practices. Mol. Immunol. 2007, 44:3076-3082.
30. Macías A., Arce S., Leon J., Mustelier G., Bombino G., Domarco A., Perez R., Lage A. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg). Hybridoma 1999, 18:263-272.
31. Mackay M., Stanevsky A., Wang T., Aranow C., Li M., Koenig S., Ravetch J.V., Diamond B. Selective dysregulation of the Fc gamma IIB receptor on memory B cells in SLE. J. Exp. Med. 2006, 203:2157-2164.
32. Malykh Y.N., Schauer R., Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001, 83:623-634.
33. Marquina G., Waki H., Fernandez L.E., Kon K., Carr A., Valiente O., Perez R., Ando S. Gangliosides expressed in human breast cancer. Cancer Res. 1996, 56:5165-5171.
34. Negi V., Sriramulu E., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., Lacroix-Desmazes S., Bayry J., Kaveri S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007, 27:233-245.
35. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol 2008, 8:34-47.
36. Poskitt D.C., Jean-Francois M.J., Turnbull S., Macdonald L., Yasmeen D. Internal image (Ab2 beta) anti-idiotype vaccines. Theoretical and practical aspects. Vaccine 1991, 9:792-796.
37. Rahman Z.S., Alabyev B., Manser T. FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell activity. J. Immunol. 2007, 178:897-907.
38. Rankin C.T., Veri M.C., Gorlatov S., Tuaillon N., Burke S., Huang L., Inzunza H.D., Li H., Thomas S., Johnson S., Stavenhagen J., Koenig S., Bonvini E. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 2006, 108:2384-2391.
39. Roque-Navarro L., Chakrabandhu K., de León J., Rodríguez S., Toledo C., Carr A., de Acosta C.M., Hueber A.O., Pérez R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther. 2008, 7:2033-2041.
40. Roque-Navarro L., Mateo C., Lombardero J., Mustelier G., Fernández A., Sosa K., Morrison S.L., Pérez R. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridom. 2003, 22:245-257.
41. Rothe A., Schulz H., Elter T., Engert A., Reiser M. Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica 2004, 89:875-876.
42. Sarmay G., Lund J., Rozsnyay Z., Gergely J., Jefferis R. Mapping and comparison of the interaction sites on the Fc region of the IgG responsible for the triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcg receptor. Mol. Immunol. 1992, 29:633-639.
43. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat. Med. 2004, 10:17-18.
44. Sibéril S., Dutertre C.A., Boix C., Bonnin E., Ménez R., Stura E., Jorieux S., Fridman W.H., Teillaud J.L. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol. Lett. 2006, 106:111-118.
45. Smith K.G., Clatworthy M.R. FcgRIIb in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328-343.
46. Tedder T.F., Klejman G., Disteche C.M., Adler D.A., Schlossman S.F., Saito H. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. J. Immunol. 1988, 141:4388-4394.
47. Vázquez A.M., Alfonso M., Lanne B., Karlsson K.A., Carr A., Barroso O., Fernández L.E., Rengifo E., Lanio M.E., Alvarez C., Zeuthen J., Pérez R. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995, 14:551-556.
48. Vázquez A.M., Pérez A., Hernández A.M., Macías A., Alfonso M., Bombino G., Pérez R. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998, 17:527-534.
49. Vollmers H.P., Brandlein S. Natural antibodies and cancer. J. Autoimmun. 2007, 29:295-302.
50. Walker J.A., Smith K.G.C. Dependence of surface monoclonal antibody binding on dynamic changes in FcgRIIb expression. Immunology 2008, 124:412-418.
51. Winkler M., Franssen J.D., Collignon C., Leo O., Mariamé B., van de Walle P., de Groote D., Urbain J. Idiotypic regulation of the immune system Common idiotypic specificities between idiotypes and antibodies raised against anti-idiotypic antibodies in rabbits. J. Exp. Med. 1979, 150:184-195.
52. Xiang Z., Cutler A.J., Brownlie R.J., Fairfax K., Lawlor K.E., Severinson E., Walker E.U., Manz R.A., Tarlinton D.M., Smith K.G. FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 2007, 8:419-429.
53. Xu D., Alegre M.L., Varga S.S., Rothermel A., Collins A.M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P., Bluestone J.A., Jolliffe L.K., Zivin R.A. In Vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol. 2000, 200:16-26.
54. Yan X., Evans S.V., Kaminki M.J., Gillies S.D., Reisfeld R.A., Houghton A.N., Chapman P.B. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. J. Immunol. 1996, 157:1582-1588.
55. Zhao Y., Lou D., Burke J., Kohler H. Enhanced anti-B-cell tumor effects with anti-CD20 superantibody. J. Immunother. 2002, 25:57-62.